Lakewood-Amedex Biotherapeutics Inc.

Lakewood-Amedex Biotherapeutics Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing locally delivered antimicrobials for infectious diseases. Its lead program is Nu-3, a Bisphosphocin® antibacterial being studied for topical treatment of mildly infected diabetic foot ulcers, alongside earlier-stage pipeline compounds and a patent portfolio covering its technologies.

— Lakewood-Amedex Biotherapeutics Inc.
%
Lead clinical candidate0% Nu-3 and related formulations being developed for topical treatment of infected wounds.
Antimicrobial platform0% Bisphosphocin®-based small-molecule compounds targeting bacterial infections and AMR.
Pipeline development0% Earlier-stage infectious disease programs under preclinical and clinical evaluation.
Intellectual property0% Issued patents and pending applications covering products and technologies in major markets.

The company does not yet sell approved products, so its immediate “customers” are not commercial buyers but regulators,...

  • Regulatory authoritiesprimary

    FDA and comparable agencies review the clinical package needed to advance Nu-3 and other candidates.

  • Clinical trial sites and investigatorsprimary

    Hospitals, clinics, and researchers conduct the safety, dose, and efficacy studies required for development.

  • Wound-care and hospital buyerssecondary

    Future commercial buyers for topical anti-infective treatments used in diabetic foot ulcers and similar infections.

  • Patients with infectious diseasessecondary

    End users who would receive locally delivered antimicrobials if the products reach market.

Lakewood-Amedex is headquartered in University Park, Florida and is organized in the United States...

  • •Headquartered in University Park, Florida, United States
  • •U.S.-based clinical development and corporate operations
  • •Patent coverage extends into major pharmaceutical markets
  • •No product revenue yet, so no commercial geography disclosed

The company’s strategy is to advance Nu-3 through clinical development, starting with safety and dose-response work and...

01
Advance Nu-3 through clinical developmentshort-term

Nu-3 is the lead asset and the main path to any future product revenue.

02
Refine pipeline indication strategymedium-term

Earlier-stage compounds need clear clinical targets before costly development.

03
Protect and monetize intellectual propertylong-term

Patent coverage supports exclusivity and future partnering or commercialization.

The company faces the typical risks of a clinical-stage biotech: development failure, regulatory delay, and uncertainty...

critical

Financing dependence

The company has no product revenue and must fund development through external capital sources.

Scope
Corporate operations and clinical programs
Materiality
high
high

Clinical development failure

Nu-3 and other candidates must prove safety and efficacy in human studies before commercialization.

Scope
Lead program and pipeline candidates
Materiality
high
high

Regulatory approval risk

Advancement depends on FDA or comparable authorities approving trial results and later marketing applications.

Scope
All product candidates
Materiality
high
medium

Antibiotic resistance and competitive science risk

AMR targets are scientifically difficult, and new therapies can be undermined by resistance or better alternatives.

Scope
Bisphosphocin® platform and infectious disease pipeline
Materiality
medium
medium

Intellectual property risk

Patent scope, validity, and enforceability are central to future exclusivity and partnering value.

Scope
68 issued patents and 36 pending applications
Materiality
medium
Research and development expense timing
Affects operating loss and comparability across periods
Stock-based compensation
Affects operating expenses and dilution analysis
Convertible notes and preferred stock
Affects interest expense, equity, and potential dilution
Going-concern and liquidity estimates
Affects risk assessment and disclosure emphasis

Immix Biopharma, Inc.

IMMX · Pharmaceutical Preparations

Dogwood Therapeutics, Inc.

DWTX · Pharmaceutical Preparations

AIM ImmunoTech Inc.

AIM · Biological Products, (No Diagnostic Substances)

BiomX Inc.

PHGE · Biological Products, (No Diagnostic Substances)

Amylyx Pharmaceuticals, Inc.

AMLX · Pharmaceutical Preparations

Biofrontera Inc.

BFRI · Pharmaceutical Preparations

: 16.6.2026